Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.

O'Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ, Krzyzanowska M, Reuther D, Chin S, Wang L, Brooks K, Hansen AR, Asa SL, Knox JJ.

Br J Cancer. 2019 Jun;120(12):1113-1119. doi: 10.1038/s41416-019-0474-x. Epub 2019 May 20.

PMID:
31105270
2.

The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.

O'Kane GM, Liu G, Stockley TL, Shabir M, Zhang T, Law JH, Le LW, Sacher A, Shepherd FA, Bradbury PA, Leighl NB.

Lung Cancer. 2019 May;131:86-89. doi: 10.1016/j.lungcan.2019.03.019. Epub 2019 Mar 20.

PMID:
31027703
3.

The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis.

O'Kane GM, Su J, Tse BC, Tam V, Tse T, Lu L, Borean M, Tam E, Labbé C, Naik H, Mittmann N, Doherty MK, Bradbury PA, Leighl NB, Shepherd FA, Richard NM, Edelstein K, Shultz D, Brown MC, Xu W, Howell D, Liu G.

Oncologist. 2019 Apr 5. pii: theoncologist.2018-0544. doi: 10.1634/theoncologist.2018-0544. [Epub ahead of print]

PMID:
30952820
4.

Outcomes of Long-term Interval Rescreening With Low-Dose Computed Tomography for Lung Cancer in Different Risk Cohorts.

Aggarwal R, Lam ACL, McGregor M, Menezes R, Hueniken K, Tateishi H, O'Kane GM, Tsao MS, Shepherd FA, Xu W, McInnis M, Schmidt H, Liu G, Kavanagh J.

J Thorac Oncol. 2019 Jun;14(6):1003-1011. doi: 10.1016/j.jtho.2019.01.031. Epub 2019 Feb 13.

PMID:
30771523
5.

Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases.

Connor AA, Denroche RE, Jang GH, Lemire M, Zhang A, Chan-Seng-Yue M, Wilson G, Grant RC, Merico D, Lungu I, Bartlett JMS, Chadwick D, Liang SB, Eagles J, Mbabaali F, Miller JK, Krzyzanowski P, Armstrong H, Luo X, Jorgensen LGT, Romero JM, Bavi P, Fischer SE, Serra S, Hafezi-Bakhtiari S, Caglar D, Roehrl MHA, Cleary S, Hollingsworth MA, Petersen GM, Thayer S, Law CHL, Nanji S, Golan T, Smith AL, Borgida A, Dodd A, Hedley D, Wouters BG, O'Kane GM, Wilson JM, Zogopoulos G, Notta F, Knox JJ, Gallinger S.

Cancer Cell. 2019 Feb 11;35(2):267-282.e7. doi: 10.1016/j.ccell.2018.12.010. Epub 2019 Jan 24.

PMID:
30686769
6.

Development and evaluation of screening dysphagia tools for observational studies and routine care in cancer patients.

Borean M, Shani K, Brown MC, Chen J, Liang M, Karkada J, Kooner S, Doherty MK, O'Kane GM, Jang R, Elimova E, Wong RK, Darling GE, Xu W, Howell D, Liu G.

Health Sci Rep. 2018 May 21;1(7):e48. doi: 10.1002/hsr2.48. eCollection 2018 Jul.

7.

Sensitive tumour detection and classification using plasma cell-free DNA methylomes.

Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O'Kane GM, Liu J, Mansour M, McPherson JD, O'Brien C, Leighl N, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD.

Nature. 2018 Nov;563(7732):579-583. doi: 10.1038/s41586-018-0703-0. Epub 2018 Nov 14.

PMID:
30429608
8.

Importance of Long-term Low-Dose CT Follow-up after Negative Findings at Previous Lung Cancer Screening.

Kavanagh J, Liu G, Menezes R, O'Kane GM, McGregor M, Tsao M, Shepherd FA, Schmidt H.

Radiology. 2018 Oct;289(1):218-224. doi: 10.1148/radiol.2018180053. Epub 2018 Jul 10.

PMID:
29989522
9.

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.

O'Kane GM, Barnes TA, Leighl NB.

Curr Oncol. 2018 Jun;25(Suppl 1):S28-S37. doi: 10.3747/co.25.3796. Epub 2018 Jun 13. Review.

10.

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.

Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O'Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA.

Cancer Discov. 2018 Sep;8(9):1112-1129. doi: 10.1158/2159-8290.CD-18-0349. Epub 2018 May 31.

PMID:
29853643
11.

Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.

O'Kane GM, Leighl NB.

CNS Drugs. 2018 Jun;32(6):527-542. doi: 10.1007/s40263-018-0526-4. Review.

PMID:
29799091
12.

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.

Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, Liang SB, Chadwick D, Zhang A, O'Kane GM, Albaba H, Moura S, Grant RC, Miller JK, Mbabaali F, Pasternack D, Lungu IM, Bartlett JMS, Ghai S, Lemire M, Holter S, Connor AA, Moffitt RA, Yeh JJ, Timms L, Krzyzanowski PM, Dhani N, Hedley D, Notta F, Wilson JM, Moore MJ, Gallinger S, Knox JJ.

Clin Cancer Res. 2018 Mar 15;24(6):1344-1354. doi: 10.1158/1078-0432.CCR-17-2994. Epub 2017 Dec 29.

13.

Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer.

O'Kane GM, Connor AA, Gallinger S.

Trends Mol Med. 2017 Dec;23(12):1121-1137. doi: 10.1016/j.molmed.2017.10.007. Epub 2017 Nov 10. Review.

PMID:
29133135
14.

Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium.

Lohavanichbutr P, Sakoda LC, Amos CI, Arnold SM, Christiani DC, Davies MPA, Field JK, Haura EB, Hung RJ, Kohno T, Landi MT, Liu G, Liu Y, Marcus MW, O'Kane GM, Schabath MB, Shiraishi K, Slone SA, Tardón A, Yang P, Yoshida K, Zhang R, Zong X, Goodman GE, Weiss NS, Chen C.

Clin Cancer Res. 2017 Dec 15;23(24):7550-7557. doi: 10.1158/1078-0432.CCR-17-1401. Epub 2017 Oct 3.

15.

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.

Barnes TA, O'Kane GM, Vincent MD, Leighl NB.

Front Oncol. 2017 May 31;7:113. doi: 10.3389/fonc.2017.00113. eCollection 2017. Review.

16.

Uncommon EGFR mutations in advanced non-small cell lung cancer.

O'Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA.

Lung Cancer. 2017 Jul;109:137-144. doi: 10.1016/j.lungcan.2017.04.016. Epub 2017 Apr 27. Review.

PMID:
28577943
17.

Is chemotherapy always required for cancer in pregnancy? An observational study.

Walsh EM, O'Kane GM, Cadoo KA, Graham DM, Korpanty GJ, Power DG, Carney DN.

Ir J Med Sci. 2017 Nov;186(4):875-881. doi: 10.1007/s11845-017-1602-3. Epub 2017 May 5.

PMID:
28477329
18.

Screening for mismatch repair deficiency in colorectal cancer: data from three academic medical centers.

O'Kane GM, Ryan É, McVeigh TP, Creavin B, Hyland JM, O'Donoghue DP, Keegan D, Geraghty R, Flannery D, Nolan C, Donovan E, Mehigan BJ, McCormick P, Muldoon C, Farrell M, Shields C, Mulligan N, Kennedy MJ, Green AJ, Winter DC, MacMathuna P, Sheahan K, Gallagher DJ.

Cancer Med. 2017 Jun;6(6):1465-1472. doi: 10.1002/cam4.1025. Epub 2017 May 3.

19.

Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.

O'Kane GM, Leighl NB.

Transl Lung Cancer Res. 2016 Dec;5(6):628-636. doi: 10.21037/tlcr.2016.09.05. Review.

20.

Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy.

Labbé C, Leung Y, Silva Lemes JG, Stewart E, Brown C, Cosio AP, Doherty M, O'Kane GM, Patel D, Cheng N, Liang M, Gill G, Rett A, Naik H, Eng L, Mittmann N, Leighl NB, Bradbury PA, Shepherd FA, Xu W, Liu G, Howell D.

Clin Lung Cancer. 2017 Jul;18(4):388-395.e4. doi: 10.1016/j.cllc.2016.12.015. Epub 2016 Dec 28.

PMID:
28111120
21.

Osteosarcoma in a Patient Receiving Long-Term TNF Inhibitor Therapy.

Greene J, O'Kane GM, Carney DN, Aherne E, O'Toole GC.

Ir Med J. 2016 Mar 10;109(3):375.

PMID:
27685822
22.

Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.

O'Kane GM, Labbé C, Doherty MK, Young K, Albaba H, Leighl NB.

Oncologist. 2017 Jan;22(1):70-80. doi: 10.1634/theoncologist.2016-0164. Epub 2016 Aug 17. Review.

23.

Transbronchial lung biopsy (TBLB) in diagnosing pulmonary alveolar proteinosis (PAP): forgotten role in Australia?

Tung AH, Grace J, O'Kane GM, Kumar K.

Respirol Case Rep. 2015 Sep 25;3(4):145-7. doi: 10.1002/rcr2.129. eCollection 2015 Dec.

24.

Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review.

O'Kane GM, Cadoo KA, Walsh EM, Emerson R, Dervan P, O'Keane C, Hurson B, O'Toole G, Dudeney S, Kavanagh E, Eustace S, Carney DN.

Clin Sarcoma Res. 2015 Jul 14;5:17. doi: 10.1186/s13569-015-0032-0. eCollection 2015.

25.

Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.

O'Kane GM, Lyons TG, Colleran GC, Ahmad MW, Alken S, Kavanagh EC, Fitzpatrick D, Murray B, Kelly CM.

Oncol Res Treat. 2014;37(12):757-60. doi: 10.1159/000368316. Epub 2014 Oct 30.

PMID:
25531722
26.

Vismodegib in the treatment of advanced BCC.

O'Kane GM, Lyons T, McDonald I, Mulligan N, Moloney FJ, Murray D, Kelly CM.

Ir Med J. 2014 Jul-Aug;107(7):215-6.

PMID:
25226719
27.

Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.

Lyons TG, O'Kane GM, Kelly CM.

Expert Opin Drug Saf. 2014 Aug;13(8):1125-32. doi: 10.1517/14740338.2014.939952. Review.

PMID:
25033383
28.
29.

Candidaemia in an Australian teaching hospital: relationship to central line and TPN use.

Stratov I, Gottlieb T, Bradbury R, O'Kane GM.

J Infect. 1998 Mar;36(2):203-7.

PMID:
9570655
30.
31.

Severe adverse reaction to moclobemide.

O'Kane GM, Gottlieb T.

Lancet. 1996 May 11;347(9011):1329-30. No abstract available.

PMID:
8622519
32.

Alterations in lymphocytes as a result of burns.

O'Kane GM, Gottlieb T, Bradbury R, Kennedy P.

Med J Aust. 1996 Apr 1;164(7):445. No abstract available.

PMID:
8609863
33.

Near-fatal septicaemia with Chromobacterium violaceum.

Georghiou PR, O'Kane GM, Siu S, Kemp RJ.

Med J Aust. 1989 Jun 19;150(12):720-1.

PMID:
2733620

Supplemental Content

Loading ...
Support Center